Hormonal therapy in advenced stage prostate cancer

Basit Öğe Kaydı
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorKodaz, Hilmi
dc.contributor.authorTurkmen, Esma
dc.date.accessioned2024-06-12T10:51:39Z
dc.date.available2024-06-12T10:51:39Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractProstat cancer is the most common type of cancer in men. At the time of diagnosis, only 5% of prostat cancer patients have the disease in advanced stage. While the 5 year overall survival rate of the patients with locoregional disease is close to 100%, this ratio in patients with advanced disease decreases to 28%. Prostat cancer cells depend on androgens for development, proliferation and physiological function. The purpose of the standard hormone therapy is to keep testesteron levels in castrate levels. Androgen deprivation therapy (ADT) is the standard treatment approach in prostat cancer patients with advanced stage. Although this treatment possesses many clinical benefits, it has also side effects affecting many systems in the body. This article evaluated the types and mechanisms of action of ADT, the management of this treatment's side effects, and the controversial situations commonly encountered in daily oncology practice in the light of current literature.en_US
dc.identifier.doi10.5505/tjoncol.2015.1088
dc.identifier.endpage33en_US
dc.identifier.issn1300-7467
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-84928593408en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage25en_US
dc.identifier.urihttps://doi.org/10.5505/tjoncol.2015.1088
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18439
dc.identifier.volume30en_US
dc.identifier.wosWOS:000362108300005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.publisherKare Publen_US
dc.relation.ispartofTurk Onkoloji Dergisi-Turkish Journal Of Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAndrogen Deprivation Therapyen_US
dc.subjectProstate Canceren_US
dc.subjectAndrogen-Deprivation Therapyen_US
dc.subjectRandomized-Trialsen_US
dc.subjectBilateral Orchiectomyen_US
dc.subjectEuropean Organizationen_US
dc.subjectCyproterone-Acetateen_US
dc.subjectGoserelin Acetateen_US
dc.subjectAmerican-Societyen_US
dc.subjectOpen-Labelen_US
dc.subjectPhase-Iiien_US
dc.subjectFollow-Upen_US
dc.titleHormonal therapy in advenced stage prostate canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu